InnoCare Pharma Limited
9969.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$19.02B
Close$
Share Statistics
| Market cap | $19.02 Billion |
|---|---|
| Enterprise Value | $14.92 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.36 |
| Beta | 0.39 |
| Outstanding Shares | 1,764,576,252 |
Return
| Return on Equity | 11.83% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 8.62% |
Valuation & Multiples
| P/E Ratio | 20.87 |
|---|---|
| PEG | -5.33 |
| Price to Sales | 12.73 |
| Price to Book Ratio | 3.18 |
| Enterprise Value to Revenue | 5.42 |
| Enterprise Value to EBIT | 19.17 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$805.67 M
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$808.05 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About InnoCare Pharma Limited
1,388 employees
CEO: Jisong Cui InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, a...